Navigation Links
Experimental drug improves muscle strength among male cancer patients
Date:6/25/2012

An experimental medication safely increases muscle strength and physical functioning among cancer patients with low testosterone levels, a new drug study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

The medication, called enobosarm, is the first of a new class of drugs known as selective androgen receptor modulators, which are similar to steroids in their growth-enhancing effects but, potentially, have fewer side effects.

Muscle wasting is a significant problem for many cancer patients due to imbalances in body systems caused by the underlying cancer. In addition, this muscle wasting may be related to low testosterone levels, or hypogonadism, which affects approximately 50 percent of men undergoing treatment for late-stage cancer. Muscle wasting can seriously limit mobility, functioning, and quality of life for affected patients.

In this multi-center drug trial, enobosarm significantly improved physical function among patients with low testosterone, as well as normal hormone levels. Among the low testosterone group, physical function improved by 19 percent, while patients with normal hormone measurements increase their functional ability by 13 percent. At the study's start, 60 percent of patients had subnormal testosterone levels, lost more weight, and suffered greater declines in physical functioning than patients with normal hormone concentrations.

"These data provide evidence that enobosarm may play an important role in the management of cancer-related muscle-wasting even in the setting of low testosterone," said study lead author Adrian Dobs, M.D., M.H.S., professor of medicine and oncology, and vice-chair of the Department of Medicine, Faculty Development at Johns Hopkins University Medical School in Baltimore, MD.

The overall study included 159 cancer patients, of which 65 percent were men. Female participants were post-menopausal, and males were >45 ye
'/>"/>

Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Experimental Drug Helps Fight Some Childhood Cancers, Study Finds
2. Experimental Drug Eases Autistic Behaviors in Mice
3. Experimental Gel May Help Those With Advanced Parkinsons
4. Experimental Pill for Multiple Sclerosis Shows Promise
5. Experimental Chemo Combo for Colon Cancer Disappoints
6. New delivery method improves efficacy of 2 common Parkinsons disease medications
7. Sleep improves functioning in Parkinsons patients, but reasons remain elusive
8. PAP therapy improves depressive symptoms in all patients with sleep apnea
9. STeleR study: Telerehab improves functioning after stroke
10. Tiny implanted coil improves lung function in patients with severe emphysema
11. Study shows antibiotic improves respiratory function in lung transplant patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... (PRWEB) May 20, 2013 According to a ... Warnings at Indoor Tanning Salons,” tanning salons in ... The Food and Drug Administration wants to see cancer warnings ... a minimum age floor of eighteen for the use of ... concerns about melanoma, which has become increasingly common over the ...
(Date:5/20/2013)... According to a June 2009 Bloomberg article, ... amount to approximately $3.6 billion dollars per year (i). ... estimated that there 15 million incidents of medical harm ... everyone who receives any form of medical treatment should ... Merriam-Webster defines malpractice as “a dereliction of professional duty ...
(Date:5/20/2013)... Osborn’s Brain: Imaging, Pathology, and ... Osborn’s 1993 award winning book Diagnostic Neuroradiology (a.k.a. “The ... neuroradiology texts. , In this highly anticipated 1,300-page ... complex topics visually appealing and easy to understand. It ... with spectacular pathology examples, relevant anatomy, and the most ...
(Date:5/20/2013)... Galveston researchers have been awarded a five-year, $1.8 million ... Stroke to apply the techniques of gene therapy to ... that arises from a malfunction in the nervous system. ... millions of Americans, manifesting itself in a variety of ... intense discomfort in response to a light touch, for ...
(Date:5/20/2013)... 20, 2013 Horizon NJ Health, New ... announced that it has earned a Commendable Accreditation ... Horizon NJ Health is a wholly owned subsidiary of ... , NCQA Health Plan Accreditation is a nationally recognized ... that health plans provide to their members. Health Plan ...
Breaking Medicine News(10 mins):Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2Health News:Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases 2Health News:Osborn’s Brain from Amirsys Publishing Receives Doody’s Top Honors 2Health News:Pain, pain, go away 2Health News:Pain, pain, go away 3Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3
... HIV positive girls will participate ,A beauty contest with ... 2005, which is the World AIDS Day, in which only ... ‘Miss Positive-2005’. The object of the contest is to change ... and also help HIV infected people lead a normal life. ...
... to two genes, both variant forms of a gene called ... in the smoking addiction.// The protein product of these genes ... the body. ,The two identified gene forms are ... metabolism of nicotine, more specifically found to account for slow ...
... heart failure patients in United States have better short-term ... over time.// ,Their study findings appear in the ... ,Heart failure is the most common cause of hospitalization ... ,The authors compared process of care and 30-day ...
... effective treatment option for patients with liver cancer. A ... to treat a patient who harbors a liver tumor ... surgical options are currently available for this group of ... the researchers who have now suggested a novel plan ...
... has found that besides being really harsh on the ears, ... Writing in the latest issue of the European Heart Journal ... mean an increased risk of heart attack. ,Researchers ... study between 1998 and 2001 in 32 hospitals in Berlin. ...
... (QBI) have now found a process that could lead ... and acquired brain injury. ,The research focuses on ... memory function and where the brain's ability to regenerate ... ,The study by Dr Natalie Bull and Professor ...
Cached Medicine News:Health News:Tendency To Smoke and Get Addicted Could Run In Families! 2Health News:Disparity In Survival Rates In US and Canadian heart Patients 2Health News:Novel Treatment Found To Prolong Survival Of Liver Cancer Patients 2Health News:Irritating Noise Increases Risk Of Heart Attacks 2Health News:Research Targets treatment for dementia and brain injuries 2
(Date:5/20/2013)... ATLANTA , May 20, 2013  Atlantic ... developed and is commercializing a unique technology to ... founder and President, Anthony Soscia ... the Atlanta Business Chronicle ,s Health-Care Heroes ... Atlanta Business Chronicle to honor individuals and ...
(Date:5/20/2013)... May 20, 2013 Enrollment of patients with ... 2b dose-finding clinical trial of product candidate NewMet ... treatment for Type 2 diabetes. Elcelyx expects to complete ... in June. Results of the trial,s primary endpoint of ... summer, and the read-out for long-term glucose lowering and ...
(Date:5/20/2013)... Md. , May 20, 2013  Neuralstem, Inc. ... Feldman , MD, PhD, principal investigator, presented updated ... stem cell (NSI-566) trial in the treatment of amyotrophic ... ,s disease) at the neuro diabetes special medical symposium ... In a talk called "Recent Therapeutic Advances in Stem ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
... contact lens cleaning solution is ... and professionally proven cleaner. A ... resulting in a very effective ... cosmetic residue, salts, mucous and ...
Round knurled handle. Overall length 130 mm....
Alvis foreign body spud 4 3/4 inches, oval curette 1 x 3 mm with fine point....
Foreign body spud angled, lightly rounded tip....
Medicine Products: